BOLD News and Press, Audentes Therapeutics Inc. From 04/08/19

The following slide deck was published by Audentes Therapeutics, Inc. in conjunction with this Read more ...

Gene therapy developer Audentes Therapeutics (NASDAQ: BOLD ) has expanded its pipeline with new programs in Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). More news on: Audentes Therapeutics, Inc., Sarepta Therapeutics, Inc., Solid Biosciences Inc., Healthcare sto...

SAN FRANCISCO , April 8, 2019 /PRNewswire/ -- Conference call and webcast Monday, April 8, 2019 at 8:30 am ET Webcast may be accessed via the Investor and Media page of the Audentes website Call may be accessed by dialing (833) 659-8620 (U.S.) or (409) 767-9247...

Audentes Therapeutics (NASDAQ: BOLD ) appoints  Mark A. Meltz, J.D. as Senior Vice President, General Counsel and Sarah J. Spencer as Vice President, Corporate Communications. More news on: Audentes Therapeutics, Inc., GlaxoSmithKline plc, Healthcare stocks news, Read more ....

NetworkNewsWire Editorial Coverage : Pharmaceutical companies are now employing advanced medical breakthroughs and new technologies, including gene therapies and nanoparticle engineering, to fight every type of cancer. Gene therapies are being developed to more effectively target the tr...

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you c...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Time to look ahead after the market came off its best two-month run in years. The e...

SAN FRANCISCO , Feb. 28, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today announced its support f...

Audentes Therapeutics (BOLD) Q4 2018 Earnings Conference Call February 27, 2019 04:30 PM ET Company Participants Andrew Chang - Director of Investor Relations Matthew Patterson - President and Chief Executive Officer Thomas Soloway - Senior Vice President and Chief Financial Offi...

Audentes Therapeutics (NASDAQ: BOLD ): Q4 GAAP EPS of -$0.84 beats by $0.07 . More news on: Audentes Therapeutics, Earnings news and commentary, Healthcare stocks news, Read more ...